MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from issuance of
common stock in...
$10,875K
Proceeds from sale of
property and equipment
$71K
Net cash provided by
financing activities
$10,875K
Net cash provided by
investing activities
$71K
Net change in cash
and cash...
-$35,458K
Canceled cashflow
$10,946K
Stock-based compensation
$7,405K
Accounts payable
$1,678K
Prepaid expenses and
other current assets
-$1,644K
Amortization of debt issuance
costs and accretion of...
$418K
Non-cash operating lease
expense
$59K
Depreciation and
amortization
$8K
Net cash used in
operating activities
-$46,404K
Canceled cashflow
$11,212K
Net loss
-$53,458K
Accrued liabilities
-$4,020K
Gain on disposal of
property and equipment
$71K
Operating lease
liabilities
-$67K
Back
Back
Cash Flow
source: myfinsight.com
Neumora Therapeutics, Inc. (NMRA)
Neumora Therapeutics, Inc. (NMRA)